NCT00279422View on ClinicalTrials.gov

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

PHASE2/PHASE3TerminatedINTERVENTIONAL

Enrollment

127

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions

Ulcerative Colitis

Interventions

DRUG

visilizumab

DRUG

visilizumab

Trial Locations (70)

1105

Amsterdam

2050

Camperdown

2170

Liverpool

2601

Argenti Döme

3000

Leuven

3128

Box Hill

3501

Csabai Kapu

4029

Herston

5042

Bedford Park

6160

Fremantle

9024

Győr, Vasvári Pál

9038

Tromsø

10021

New York

10029

New York

13353

Berlin

18055

Rostock

24105

Kiel

29425

Charleston

30342

Atlanta

30625

Hanover

31201

Macon

32608

Gainesville

33606

Tampa

40202

Louisville

40536

Lexington

46202

Indianapolis

52621

Tel Litwinsky

55905

Rochester

59037

Lille

60637

Chicago

61001

Kharkiv

64329

Tel Aviv

65025

Odesa

70376

Stuttgart

80054

Amiens

81369

Mickieviczova

90048

Los Angeles

92110

Clichy

94115

San Francisco

02115

Boston

Unknown

Pittsburgh

Nashville

South Brisbane

Fitzroy

Parkville

Vienna

Roeselare

Prague

Marseille

Nantes

Nice

Paris

Freiburg im Breisgau

München

Haifa

Rotterdam

Prinsens

77555-0764

Galveston

B-9000

Ghent

T2N 4N1

Calgary

N685W9

London

625 00

Brno

D-60431

Frankfurt

H-1083

Budapest

H-1088

Budapest

H-4012

Debrecen

H-7100

Szekszárd

H-8220

Veszprém

N-0027

Oslo

01021

Kyiv

Sponsors

Lead Sponsor

Collaborators (1)

PDL BioPharma, Inc.

All Listed Sponsors

collaborator

PDL BioPharma, Inc.

INDUSTRY

lead

Facet Biotech

INDUSTRY

NCT00279422 - A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis | Biotech Hunter | Biotech Hunter